SK Biopharmaceuticals Co., Ltd.
326030
Helyezés a részvények között
#4039
SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the... SK Biopharmaceuticals Co., Ltd. is a pharmaceutical enterprise dedicated to the research, identification, and development of novel therapies for central nervous system (CNS) disorders. Their product portfolio features Cenobamate, indicated for the treatment of epilepsy, and Solriamfetol, which addresses excessive daytime sleepiness experienced in conditions like narcolepsy or obstructive sleep apnea. The company's robust clinical pipeline includes Carisbamate, currently in Phase 1b/2 trials for Lennox-Gastaut syndrome, and Relenopride, advancing through Phase 2 for a rare neurological disease. Additionally, they have several candidates in Phase 1 development: SKL13865 for attention deficit/hyperactivity disorder (ADHD), SKL20540 for schizophrenia, SKL-PSY for bipolar disorder, and SKL24741, another potential treatment for epilepsy. Founded in 2011, the company is headquartered in Seongnam, South Korea, and functions as a subsidiary of SK Inc.
Részvényárfolyam
$51.65
Piaci kapitalizáció
$4.05B
Változás (1 nap)
0.27%
Változás (1 év)
-30.95%
Ország
KR
Kereskedés SK Biopharmaceuticals Co., Ltd. (326030)
Kategória
Healthcare
SK Biopharmaceuticals Co., Ltd. (326030) P/B aránya
P/B arány ekkor: October 2026 TTM: 5.32
SK Biopharmaceuticals Co., Ltd. legfrissebb pénzügyi jelentései és részvényára alapján a vállalat jelenlegi könyv szerinti árfolyam aránya (P/B, TTM) 5.32. 2024 végén ez az arány 15.93 volt.
P/B arány története a(z) SK Biopharmaceuticals Co., Ltd. esetén 2011 és 2026 között
P/B arány az év végén
| Év | P/B arány | Változtassa meg |
|---|---|---|
| 2026 (TTM) | 5.32 | -100.00% |
| 2025 | 0.00 | -100.00% |
| 2024 | 15.93 | -44.04% |
| 2023 | 28.46 | 61.13% |
| 2022 | 17.66 | 3.07% |
| 2021 | 17.14 | -46.44% |
| 2020 | 32.00 | -105.05% |
| 2019 | -633.75 | -570.11% |
| 2018 | 134.81 | 0.30% |
| 2017 | 134.41 | 212.50% |
| 2016 | 43.01 | 22.07% |
| 2015 | 35.23 | 21.42% |
| 2014 | 29.02 | -14.39% |
| 2013 | 33.89 | 23.27% |
| 2012 | 27.50 | 16.93% |
| 2011 | 23.51 | 0.00% |
P/B arány hasonló vállalatoknál vagy versenytársaknál
| Vállalat | P/B arány | P/B arány különbség | Ország |
|---|---|---|---|
| 6.251 | 17.52% |
US
|
|
| 13.2547 | 149.19% |
US
|
|
| 4.208 | -20.89% |
AU
|
|
| 6.1824 | 16.23% |
NL
|
|
| - | - |
CH
|
